Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The blood concentration profiles of most antimalarial drugs vary considerably between patients. The interpretation of antimalarial drug trials evaluating efficacy and effectiveness would be improved considerably if the exposure of the infecting parasite population to the antimalarial drug treatment could be measured. Artemisinin combination treatments are now recommended as first-line drugs for the treatment of falciparum malaria. Measurement of the blood, serum or plasma concentration of the slowly eliminated partner antimalarial drug on day 7 of follow-up is simpler and might be a better determinant of therapeutic response than the area under the concentration-time curve. Measurement of the day-7 drug level should be considered as a routine part of antimalarial drug trials.

Original publication

DOI

10.1016/j.pt.2008.01.006

Type

Journal article

Journal

Trends Parasitol

Publication Date

04/2008

Volume

24

Pages

159 - 163

Keywords

Animals, Antimalarials, Area Under Curve, Artemisinins, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Malaria, Microbial Sensitivity Tests, Treatment Outcome